ECM
EIGR

Element Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Element Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-597
Closed -$141K – 105
2017
Q2 		$141K Buy
+597
New +$136K 0.03% 123

Other funds holding EIGR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Element Capital Management's EIGR Position: Q3 2017 in Review

Element Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 597 shares — an estimated $141K sold.

Element Capital Management first reported a position in EIGR in Q2 2017 and held it in 1 quarter. The position peaked at $141K in Q2 2017. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

  • Element Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 597 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $141K.
  • Element Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $141K in Q2 2017.
  • 33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.